

Changes in S100B and troponin levels in a fetal sheep model of worsening acidosis

Yasmine Ould Hamoud, J. D. Pekar, Elodie Drumez, Laure Lacan, Patrice Maboudou, Julien de Jonckheere, Laurent Storme, Veronique Debarge, Dyuti Sharma, Charles Garabedian, et al.

▶ To cite this version:

Yasmine Ould Hamoud, J. D. Pekar, Elodie Drumez, Laure Lacan, Patrice Maboudou, et al.. Changes in S100B and troponin levels in a fetal sheep model of worsening acidosis. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2021, European Journal of Obstetrics & Gynecology and Reproductive Biology, 264, p. 173-177. 10.1016/j.ejogrb.2021.06.042. hal-04540490

HAL Id: hal-04540490 https://hal.univ-lille.fr/hal-04540490

Submitted on 22 Jul 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



- 1 Changes in S100B and troponin levels in a fetal sheep model of worsening acidosis.
- 3 Yasmine Hamoud¹, Jean David Pekar², Elodie Drumez³, Laure Lacan⁴, Patrice Maboudou²,
- 4 Julien De Jonckheere⁵, Laurent Storme⁶, Véronique Houfflin-Debarge¹, Dyuti Sharma⁷,
- 5 Charles Garabedian¹, Louise Ghesquière¹

6 ABBREVIATIONS

7 HIE: hypoxic-ischemic encephalopathy

8 HI: hypoxia-ischemia

9 FHR: fetal heart rate

10 c-TnT: cardiac troponin T

11 UCO: umbilical cord occlusion

12 ABSTRACT

- Background S100B and cardiac troponin T (c-TnT) are relevant biomarkers at birth of hypoxic-ischemic encephalopathy (HIE) and myocardial ischemia secondary to metabolic
- acidosis during labor, respectively. The purpose was to assess in-utero changes in S100B and
- 16 c-TnT levels in an experimental model of labor-like acidosis.
- 17 Methods Repeated umbilical cord occlusions (UCOs) in ten experiments were performed in
- mild (phase A, 1 UCO/5 mn), moderate (phase B, 1 UCO/3 mn), and severe (phase C, 1
- 19 UCO/2 mn) period. The experiments were stopped if arterial pH reached 6.90.
- Results UCOs resulted in fetal acidosis with pH dropping to 6.99 \pm 0.13. When compared
- 21 to the baseline period fetal S100B increased between phases A and B ($7\% \pm 4$ vs $17\% \pm 13$, p
- = 0.030) and between phases A and C ($7\% \pm 4$ vs $24\% \pm 8$, p < 0.001). Fetal c-TnT serum
- levels increased during occlusions: 102 ng/L (58-119) in phase A, vs 119 ng/L (103-198) in
- phase B vs 169 ng / L (128-268) in phase C (p<0.05, for all). When compared to the baseline
- 25 control period, fetal ΔcTnT was significantly modified throughout UCO series: 5.0% (-3; 45)
- 26 in phase A, 51% (4; 263) in phase B, and 77% (56.5; 269) in phase C (p< 0.05 for all).
- 27 Conclusions S100B and c-TnT increased when fetal acidosis occurred, which reflects the
- potential neurological damage and fetal cardiovascular adaptation.

30

29

31 Key words: S100B, cardiac troponin T, acidosis, fetal sheep, biomarker, perinatal asphyxia

32 Introduction

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

Uterine contractions can reduce uteroplacental perfusion by up to 60% leading to progressive fetal hypoxia (1). At term, healthy fetuses are able to withstand this transient hypoxia by reducing oxygen consumption and redirecting the oxygenated blood flow to critical organs (heart, brain, and adrenals) through activation of the peripheral chemoreflex (2,3). Providing there is adequate time for fetoplacental reperfusion between contractions, this mechanism protects fetuses from severe and irreversible hypoxic injuries. However, some fetuses develop intrapartum metabolic acidemia which remains a leading cause for neonatal complications, such as stillbirth, hypoxic-ischemic encephalopathy (HIE) and cerebral palsy. In the past decade, tissue-specific biochemical damage markers, such as S100B and cardiac troponin T (c-TnT) have been examined in umbilical cord blood at birth (4,5). The calciumbinding S100B protein is mainly concentrated in the glial cells of the nervous system. S100B has been presented as the most promising neurobiomarker in neonates with birth asphyxia (6). The increase in S100B concentration in body fluids, such as cerebrospinal fluid, blood, or urine, is a reliable marker of brain damage following asphyxia in neonates (7). The advanced hypothesis is that in case of brain lesions, some of the S100B released by the affected tissue could spread through the blood-brain barrier into the systemic circulation. In neonates suffering from severe forms of HIE, S100B is elevated in umbilical cord blood samples at birth and is associated with the severity of disease and risk of further neurodevelopmental sequelae (8). Cardiac troponin T is commonly used as a myocardial ischemia marker in both adults and infants. Studies have shown that in perinatal asphyxia, it could also be a strong and useful predictor of myocardial injury in birth asphyxia and HIE (9). Costa et al. reported that asphyxiated neonates had higher c-TnT levels associated with decreased cardiac output when compared with control healthy newborns (10). Yet, the degree of prematurity, fetal weight and type of delivery may complicate the assessment (11).

- 57 The in-utero levels of these biomarkers in response to worsening acidosis have still not been
- described. The purpose of this study was to assess the changes in S100B and c-TnT levels in
- both fetal and maternal serums in an experimental model of severe labor-like acidosis.

- Materials and methods
- 61 Surgical preparation
- Near-term pregnant sheep (Ile de France, INRA, Val de Loire, France) with a gestational age
- of 124 ± 1 days (term = 145 days) underwent our surgical procedure, as described previously
- 64 (12,13). If an ewe had multiple fetuses, only one was instrumented and included in the
- experiment.
- 66 For anesthesia, ewes had a vascular infusion of 500 mL of Ringer lactate, then a
- 67 premedication of 0.3 mL intravenous Sedaxylan (xylazine 20mg/ml; Dechra, The
- Netherlands). Induction was made with isoflurane 5% before intubation, and anesthesia was
- 69 maintained with soflurane 2% (14). After maternal laparotomy and hysterotomy, catheters
- 70 (4-Fr diameter; Arrow, Reading, PA, USA) were placed in the fetal axillary arteries. The
- 71 catheter tips were advanced to the ascending aorta. Four electrocardiogram (ECG) electrodes
- 72 (Mywire 10; Maquet, Rastatt, Germany) were placed on the fetal intercostal muscles to
- 73 record fetal ECG. An inflatable silicone occluder (OC16; In Vivo Metric, Healdsburg, CA,
- 74 USA) was placed around the umbilical cord and the volume of saline solution required to
- achieve complete occlusion was determined.
- 76 The ewes were acclimatized to the experiment room 1 hour a day in the presence of the main
- investigators in charge of carrying out the experiments.
- 78 The experimental protocol began 4 days after the surgery. After 1 hour of baseline period,
- 79 repetitive umbilical cord occlusions (UCOs) were performed by injecting an isotonic solution
- 80 into the occluder to obtain a total occlusion for 1 minute. The protocol was divided into three
- periods of 1 hour each, as described previously by Prout et al (15). During the mild phase,
- UCOs were repeated every 5 minutes (phase A). During the second phase (phase B), the
- rhythm was of one UCO every 3 minutes. Finally, the last period (phase C) consisted of one

- 84 UCO every 2 minutes. The protocol was stopped before the end of phase C if pH reached
- 85 6.90 or below.
- 86 Euthanasia was performed either at the end of the experimental procedure, or in cases of
- 87 spontaneous labor, in-utero fetal death, or death during surgery, by intravenous injection of 6
- 88 mL/50 kg of T61 (1 mL contains embutramide 200mg + mebezonium 26.92 mg + tetracaine
- 4.39 mg, MSD France, Courbevoie, France) (14).
- 90 Monitoring parameters and measurement techniques
- 91 Arterial blood gas parameters were measured with the i-STAT 1 blood analyzer (i-STAT 1
- 92 System; Abbott Point of Care, Inc, Princeton, NJ, USA) using CG4+ cartridges at specific
- 93 time points. Hemodynamic data were recorded continuously throughout the experiment. The
- 94 fetal arterial and intra-amniotic catheters were connected to pressure sensors (Pressure
- 95 Monitoring Kit 1; Baxter, Guyancourt, France) that were connected to a blood pressure
- 96 monitor (Monitor Merlin, Hewlett Packard, Palo Alto, CA, USA). The arterial blood pressure
- 97 (ABP) was measured from the blood pressure phasic signal and referenced to the intra-
- 98 amniotic pressure (IAP) (calculated ABP = observed ABP observed IAP). Biochemical
- 99 assays were performed from serum on a Cobas 8000 module e601 (Roche, Basel,
- Switzerland) using the electrochimiluminescence method. S100B and c-TnT were measured
- in both the mother (M S100B or M c-TnT) and fetus (F S100B or F c-TnT). Collected blood
- samples were centrifuged at 3500 g for 10 minutes and supernatant stored at 80° C until
- assessment. Delta S100B and c-TnT were defined as the difference in percentage of increase
- or decrease compared to the baseline control period (F Δ S100B, M Δ S100B and F Δ c-
- TnT). During the baseline period, every 20 minutes during each UCO phase and at the end of
- 106 each UCO phase, a 5-minute period with no UCO was observed to assess fetal
- hemodynamics, mean arterial blood pressure (Mean ABP), fetal heart rate (FHR), and arterial
- blood gases. We analyzed the data from the baseline period and from the 5-minute intervals

in between each UCO phases where an additional blood sample was performed for S100B

and c-TnT dosages.

111 Statistics

The gaussian variables are described in terms of mean and standard deviation and non-Gaussian variables in terms of median and interquartile range. The normality of the numerical variables was verified graphically and tested using the Shapiro-Wilk test. Parameter changes during the occlusion phases were evaluated using a mixed linear model with an unstructured covariance structure to account for the correlation between repeated measures and time and baseline data were included as fixed effects. Post-hoc comparisons between the three occlusion phases were performed using linear contrasts. The normality of the residues was verified graphically. In case of normality deviation (without possible log transformation), the comparisons between the three occlusion phases were performed using Wilcoxon's signed-rank test. Bilateral tests were performed with a significance level of 5%. Correlations between biomarker serum levels and acidemia parameters during occlusion phases (at all time of measures) were evaluated using linear mixed models by including sheep as a random effect and time as afixed effect. Statistical analyses were performed using the SAS software (v. 9.4; SAS Institute, Cary, NC, USA).

126 Ethical approval

The use of anesthesia, surgical procedure, and experimental protocol were consistent with the recommendations of the Ministry of Higher Education and Research. This study was approved by the Animal Experimentation Ethics Committee (Comité d'Ethique en Expérimentation Animale, Avis N°2016121312148878).

- 131 Results
- Fourteen ewes were instrumented. Four were excluded from our analysis: two fetuses died in
- utero at postoperative day 1, one delivery occurred at postoperative day 3 and one occluder
- ruptured during the first phase of UCO.
- Ten experiments were performed. Nine ewes had a multiple gestation (Table 1). Five fetuses
- reached endpoint before the end of the experiment: one during phase B and the other four
- during phase C.
- During the baseline control period, all measurements of FHR, mean ABP, and arterial blood
- gases were in the normal range (Table 2).
- There was no significant difference between phases A, B, and C for heart rate and mean
- ABP. There was a significant difference in UCO ABP between phases A and C (54.7 \pm 6.2 vs
- 36.1 \pm 17.2, p = 0.009) and between phases B and C (47.1 \pm 15.1 vs 36.1 \pm 17.2, p = 0.006).
- Partial pressure of oxygen (PaO₂) was not modified while partial pressure of carbon dioxide
- 144 (PaCO₂) increased significantly between phases A and C (53 mmHg ± 5.1 vs 69.9 mmHg ±
- 145 16.7, p = 0.006). pH decreased significantly throughout UCO series: 7.29 (7.21-7.37) in
- phase A vs 7.15 (7.02-7.28) in phase B vs 6.99 (6.86-7.12) in phase C (p < 0.05, for all).
- Lactates increased significantly between the 3 occlusion phases, 5.88 ± 2.35 in phase A vs
- 148 11.14 \pm 3.93 in phase B vs 15.25 \pm 1.56 in phase C (p < 0.05 for all). Base excess also varied
- significantly from -1.2 \pm 6.3 in phase A to -8.5 \pm 7.3 in phase B to -14.8 \pm 5 in phase C (p <
- 150 0.05, for all).
- Serum levels of fetal S100B increased progressively between phases A and B, 11.5 μ g \pm 3.8
- vs 12.9 μ g \pm 4.4, p < 0.001. We observed a significant difference in fetal S100B serum
- 153 concentration when compared to baseline period (ΔS100B), with a progressive increase
- between phases A and B ($7\% \pm 4$ vs $17\% \pm 13$, p = 0.030) and between phases A and C (7%
- 155 $\pm 4 \text{ vs } 24\% \pm 8, p < 0.001$).

Fetal c-TnT serum levels increased during occlusions: 102 ng/L (58-119) in phase A, vs 119 ng/L (103-198) in phase B vs 169 ng/L (128-268) in phase C (p < 0.05, for all). When compared to the baseline control period, fetal ΔcTnT was significantly modified throughout OCT series: 5.0% (-3; 45) in phase A, 51% (4;263) in phase B, and 77% (56.5; 269) in phase C (p < 0.05 for all). There was no difference observed in the maternal S100B and c-TnT dosages throughout the experiment.

Finally, we found a significant correlation between differences in biomarker serum levels throughout the experiment and acidemia parameters, such as pH, lactate, and base excess (Table 3).

165 Discussion

167

168

169

170

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

166 Main findings

Fetal hypoxia and its early detection during labor remains a major perinatal challenge. The aim is to reduce perinatal asphyxia and its complications, such as HIE. When reproducing a progressive and severe hypoxemia in near-term fetal sheep, we observed a significant rise in fetal S100B and c-TnT serum levels while pH decreases, and lactates rise.

171 Interpretation

HIE is defined as the clinical manifestation of impaired neonatal brain function following asphyxia due to an antenatal and/or perinatal adverse event (16). Various criteria (biological, clinical and sometimes electrophysiological) are used to define the severity of the neurological damage, many of them included in Sarnats' original classification (16). HIE pathogenesis is fairly complex and is still not understood fully. During HI insult, different intracellular mechanisms are activated, which in turn lead to focal or diffuse cell damage associated with a significant increase in neurobiomarkers, such as S100B (17). S100B is an acid calcium-binding protein specific to the central nervous system where it appears abundant in Schwann cells, glial cells, and neurons. Recently, a series of studies have found that the evaluation of S100B in different body fluids can help early diagnosis of neonates with perinatal asphyxia complicated with HIE (7). In particular, in cord blood samples at birth, S100B was significantly higher in infants with moderate or severe HIE. Increased concentrations were detected 48-72 hours before any clinical, laboratory, or ultrasound signs of brain damage. To our knowledge, the modification of S100B levels during a labor-like acidosis has not yet been evaluated. In our study, we observed an increase in S100B levels during the different phases of the experiment and this increase seems to be detectable as early as the onset of hypoxia, before pH drops below 7.00. In a different model of fetal hypoxia, Giussani et al. reported that, S100B concentrations increased significantly during acute hypoxemia by $24.9 \pm 2.9 \%$ (18). In human studies, the difference in S100B concentrations at birth is statistically significant between neonates with HIE and controls (8,19). The sensitivity of this neurobiomarker could be useful in daily practice as a second-line method for screening fetuses at risk of brain damage. Regarding S100B in maternal blood, an increased concentration has been reported within 3 hours of fetal hypoxic insult. Since no damage was seen in the maternal brain of the animals used, the authors concluded that some of the higher maternal S100B levels were of fetal origin, from across the placental barrier (20). In our study, we did not show any increase in maternal serum levels of S100B in response to severe hypoxia. The possibility of species-specific placental transport of the S100B may explain our differences from the literature. During labor, several adaptive mechanisms such as heart rate decelerations or tachycardia, allow fetuses to withstand hypoxia (21,22). Following a perinatal HI insult, oxygen deprivation causes myocardial damage and neonates develop cardiovascular dysfunction as part of the multiorgan failure showcasing HIE (23,24). The cTnT concentration is higher in newborns developing HIE compared to those who developed no complications (9). In our study, we found that c-TnT increased early as the pH starts to drop below 7.15. These results reinforce the hypothesis of an anaerobic cardiac metabolism secondary to fetal hypoxia. Similarly, Sweetman et al. showed that neonates with severe neonatal hypoxic ischemia have significantly higher serum c-TnT concentrations than other asphyxiated groups (5). Troponin T may be a reliable marker of myocardial injury and may serve as an adjunct for early diagnosis of perinatal asphyxia.

211 Strengths and limitations

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

212

213

214

This study provides data on progressive changes in fetal levels of S100B and c-TnT. There is a clinical interest in understanding how these markers behave during the equivalent of a very challenging labor. However, the small number of experiments and important variability of

results are obstacles to drawing strong conclusions. The baseline state of our fetuses prior to resuming the experiment was not comparable to previous reports, because PaO_2 was low and lactates elevated. We hypothesized that with the breed used and the high rate of multiple gestation, theb fetuses were not comparable to previous studies. The absence of a control group can be discussed, but the biomarker changes were compared to baseline values. Finally, a pH < 6.90 indicated the end of the experiment. Even if models that used pH as a cut off show minimal injury (15,25) compared to those that use hypotension (26), we observed mild to severe hypotension during phase C in our study.

- 223 Conclusion
- 224 S100B and c-TnT increased when fetal acidosis occurred, reflecting potential neurological
- damage and fetal cardiovascular adaptation. It will be interesting to correlate those changes to
- anatomopathology in a larger sample.

227	Competing interests
228	The authors have no conflicts of interest
229	
230	Author contributions
231	Y.H., J.D.P, D.S. and L.G. conducted the experiments. Y.H., J.D.P. and L. L collected all
232	data. Y.H. and C.G. wrote the manuscript. E.D. conducted statistical analysis and wrote the
233	statistics methodology. J.D., P.M., V.H.D. and L.S. reviewed and corrected the manuscript.

- 234 References
- 235 1. Turner JM, Mitchell MD, Kumar SS. The physiology of intrapartum fetal compromise
- 236 at term. Am J Obstet Gynecol. 2020;222(1):17–26.
- 237 2. Garabedian C, De Jonckheere J, Butruille L, Deruelle P, Storme L, Houfflin-Debarge
- V. Understanding fetal physiology and second line monitoring during labor. J Gynecol Obstet
- 239 Hum Reprod. 2017 Feb;46(2):113–7.
- 240 3. Lear CA, Wassink G, Westgate JA, Nijhuis JG, Ugwumadu A, Galinsky R, et al. The
- 241 peripheral chemoreflex: indefatigable guardian of fetal physiological adaptation to labour. J
- 242 Physiol. 2018;596(23):5611–23.
- 243 4. Beharier O, Kahn J, Shusterman E, Sheiner E. S100B a potential biomarker for early
- 244 detection of neonatal brain damage following asphyxia. J Matern-Fetal Neonatal Med Off J
- Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet. 2012
- 246 Sep;25(9):1523-8.
- 5. Sweetman D, Armstrong K, Murphy JFA, Molloy EJ. Cardiac biomarkers in neonatal
- 248 hypoxic ischaemia. Acta Paediatr Oslo Nor 1992. 2012 Apr;101(4):338–43.
- 249 6. Satriano A, Pluchinotta F, Gazzolo F, Serpero L, Gazzolo D. The potentials and
- limitations of neuro-biomarkers as predictors of outcome in neonates with birth asphyxia.
- 251 Early Hum Dev. 2017 Feb 1;105:63–7.
- 252 7. Gazzolo D, Pluchinotta F, Lapergola G, Franchini S. The Ca2+-Binding S100B
- 253 Protein: An Important Diagnostic and Prognostic Neurobiomarker in Pediatric Laboratory
- Medicine. Methods Mol Biol Clifton NJ. 2019;1929:701–28.
- 255 8. Zaigham M, Lundberg F, Olofsson P. Protein S100B in umbilical cord blood as a
- potential biomarker of hypoxic-ischemic encephalopathy in asphyxiated newborns. Early
- 257 Hum Dev. 2017;112:48–53.
- 258 9. Jones R, Heep A, Odd D. Biochemical and clinical predictors of hypoxic-ischemic

- encephalopathy after perinatal asphyxia. J Matern-Fetal Neonatal Med Off J Eur Assoc
- Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet. 2018 Mar;31(6):791–6.
- 261 10. Costa S, Zecca E, De Rosa G, De Luca D, Barbato G, Pardeo M, et al. Is serum
- troponin T a useful marker of myocardial damage in newborn infants with perinatal
- 263 asphyxia? Acta Paediatr Oslo Nor 1992. 2007 Feb;96(2):181–4.
- 264 11. Kocylowski RD, Dubiel M, Gudmundsson S, Sieg I, Fritzer E, Alkasi O, et al.
- 265 Biochemical tissue-specific injury markers of the heart and brain in postpartum cord blood.
- 266 Am J Obstet Gynecol. 2009 Mar;200(3):273.e1-273.e25.
- 267 12. Garabedian C, Clermont-Hama Y, Sharma D, Aubry E, Butruille L, Deruelle P, et al.
- 268 Correlation of a new index reflecting the fluctuation of parasympathetic tone and fetal
- acidosis in an experimental study in a sheep model. PLOS ONE. 2018 Jan
- 270 10;13(1):e0190463.
- 271 13. Ghesquière L, De Jonckheere J, Drumez E, Sharma D, Aubry E, Deruelle P, et al.
- 272 Parasympathetic nervous system response to acidosis: evaluation in an experimental fetal
- sheep model. Acta Obstet Gynecol Scand. 2018 Dec 19;
- 274 14. Vanspranghels R, De Jonckheere J, Drumez E, Lauriot Dit Prevost A, Sharma D,
- 275 Ghesquiere L, et al. Autonomic response to fetal acidosis using an experimental sheep model.
- Eur J Obstet Gynecol Reprod Biol. 2020 Mar;246:151–5.
- 277 15. Prout AP, Frasch MG, Veldhuizen RAW, Hammond R, Ross MG, Richardson BS.
- 278 Systemic and cerebral inflammatory response to umbilical cord occlusions with worsening
- acidosis in the ovine fetus. Am J Obstet Gynecol. 2010 Jan;202(1):82.e1-9.
- 280 16. Debillon T, Bednarek N, Ego A, LyTONEPAL Writing Group. LyTONEPAL: long
- term outcome of neonatal hypoxic encephalopathy in the era of neuroprotective treatment
- with hypothermia: a French population-based cohort. BMC Pediatr. 2018 01;18(1):255.
- 283 17. Lv H, Wang Q, Wu S, Yang L, Ren P, Yang Y, et al. Neonatal hypoxic ischemic

- encephalopathy-related biomarkers in serum and cerebrospinal fluid. Clin Chim Acta Int J
- 285 Clin Chem. 2015 Oct 23;450:282–97.
- 286 18. Giussani DA, Thakor AS, Frulio R, Gazzolo D. Acute Hypoxia Increases S100β
- 287 Protein in Association with Blood Flow Redistribution away from Peripheral Circulations in
- 288 Fetal Sheep. Pediatr Res. 2005 Aug;58(2):179–84.
- 289 19. Nagdyman N, Kömen W, Ko HK, Müller C, Obladen M. Early biochemical indicators
- of hypoxic-ischemic encephalopathy after birth asphyxia. Pediatr Res. 2001 Apr;49(4):502–
- 291 6.
- 292 20. Garnier Y, Frigiola A, Li Volti G, Florio P, Frulio R, Berger R, et al. Increased
- 293 maternal/fetal blood S100B levels following systemic endotoxin administration and
- 294 periventricular white matter injury in preterm fetal sheep. Reprod Sci Thousand Oaks Calif.
- 295 2009 Aug;16(8):758–66.
- 296 21. Vintzileos AM, Smulian JC. Decelerations, tachycardia, and decreased variability:
- 297 have we overlooked the significance of longitudinal fetal heart rate changes for detecting
- intrapartum fetal hypoxia? Am J Obstet Gynecol. 2016;215(3):261–4.
- 299 22. Giussani DA. The fetal brain sparing response to hypoxia: physiological mechanisms.
- 300 J Physiol. 2016 Mar 1;594(5):1215–30.
- 301 23. Polglase GR, Ong T, Hillman NH. Cardiovascular Alterations and Multiorgan
- 302 Dysfunction After Birth Asphyxia. Clin Perinatol. 2016 Sep;43(3):469–83.
- 303 24. Badurdeen S, Roberts C, Blank D, Miller S, Stojanovska V, Davis P, et al.
- 304 Haemodynamic Instability and Brain Injury in Neonates Exposed to Hypoxia–Ischaemia.
- 305 Brain Sci [Internet]. 2019 Feb 27;9(3).
- 306 25. Xu A, Matushewski B, Nygard K, Hammond R, Frasch MG, Richardson BS. Brain
- 307 Injury and Inflammatory Response to Umbilical Cord Occlusions Is Limited With Worsening
- Acidosis in the Near-Term Ovine Fetus. Reprod Sci Thousand Oaks Calif. 2016;23(7):858–

- 309 70.
- 310 26. De Haan HH, Gunn AJ, Williams CE, Gluckman PD. Brief repeated umbilical cord
- 311 occlusions cause sustained cytotoxic cerebral edema and focal infarcts in near-term fetal
- 312 lambs. Pediatr Res. 1997 Jan;41(1):96–104.

Ewes	Number of fetuses	umber of fetuses Weight of instrumented fetus		Phase
4	•	2005	**	C
1	2	3805	Yes	C
2	3	2935	No	
3	2	3555	Yes	В
4	2	3850	Yes	C
5	2	3135	No	
6	2	3150	Yes	C
7	2	3380	No	
8	2	3245	Yes	C
9	2	3290	No	
10	1	3125	No	
10	-	0.120	110	

Table 1. Description of our study group Weights are presented in grams

	Baseline	Umbilical Cord Occlusions Period			p		
	S	A	В	С	A vs B	A vs C	B vs C
FHR (bpm)	183.3 ± 10.6	172.2 ± 16.6	181.3 ± 23.1	176.4 ± 22.5	.17	.79	.45
Mean ABP (mmHg)	47.4 ± 10.8	55.3 ± 10.5	58.1 ± 8.0	59.7 ± 9.3	.35	.35	.52
UCO ABP (mmHg)	-	54.7 ± 6.2	47.1 ± 15.1	36.1 ± 17.2	.15	.009	.006
рН	7.39 ± 0.03	7.29 ± 0.08	7.15 ± 0.13	6.99 ± 0.13	.001	<.001	.002
PaO ₂ (mmHg)	13.6 ± 5.5	14.0 ± 3.8	15.2 ± 2.9	16.3 ± 2.7	.12	.078	.17
PaCO ₂ (mmHg)	46.8 ± 6.2	53.0 ± 5.1	57.2 ± 7.0	69.9 ± 16.7	.002	.006	.013
Base excess (mEq/L)	3.1 ± 4.6	-1.2 ± 6.3	-8.5 ± 7.3	-14.8 ± 5.0	<.001	<.001	<.001
Lactate (mmol/L)	2.51 ± 0.74	5.88 ± 2.35	11.14 ± 3.93	15.25 ± 1.56	<.001	<.001	.008
M S100B (μg/L)	0.44 ± 0.16	0.47 ± 0.14	0.43 ± 0.16	0.45 ± 0.19	.70	.67	.48
M Δ S100B (%)	-	-1.9 ± 2.7	-2.0 ± 5.6	-0.8 ± 0.13	.93	.98	.95
F S100B (μg/L)	10.7 ± 3.4	11.5 ± 3.8	12.7 ± 4.7	12.9 ± 4.4	.032	.001	.14
F Δ S100B (%)	-	7 ± 4	17 ± 13	24 ± 8	.030	<.001	.18
$M \text{ c-TNT } (ng/L)^1$	8 (6; 14)	8.5 (6; 12)	9 (6; 14)	10.5 (6; 15)	.75	1	1
M Δ c-Tnt (%)	-	6.3 ± 7.9	3.3 ± 11.5	3.5 ± 15.7	.33	.87	.51
$F c-TnT (ng/L)^1$	73 (49 ; 105)	102 (58; 119)	119 (103; 198)	169 (128; 268)	.012	.008	.008
$F \Delta c$ -TnT (%) ¹	-	5.0 (-3.0; 45.0)	51.0 (4.0; 263.0)	77.0 (56.5; 269.0)	.012	.008	.008

³¹⁷ Table 2. Hemodynamic, blood gas and biochemical measures

321 Umbilical Cord Occlusion

Data are presented on average ± standard or median deviation (interquartile range).

³¹⁹ 1 P-values were calculated using the Wilcoxon signed-rank test, p < .05 is significant (given in bold)

³²⁰ FHR: Fetal Heart Rate, bpm: beats per minutes, ABP: Arterial Blood Pressure, F: Fetal, M: Maternal, cTnT: Cardiac Troponin T; UCO:

	рН		Lactate		Base excess	
F Δ S100B	-0.049 ± 0.16	0.007	1.271 ± 0.295	<0.001	-2.193 ± 0.559	0.002
F Δ c-TnT	-0.001 ± 0.001	0.034	0.016 ± 0.005	0.004	-0.024 ± 0.009	0.021

- Table 3. Correlations between biomarker serum levels with acidemia parameters.
- 324 Data are presented on $\beta \pm$ standard error.
- p < .05 is significant (given in bold).